Back to results
US 7,626,015 B2Granted
Therapeutic uses of inhibitors of RTP801L
AssigneeQuark Pharmaceuticals, Inc.
InventorsElena Feinstein, Igor Mett
Life of this patent
Estimating the term…
Abstract
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.
Claims6
A compound having the structure:
- wherein alternating ribonucleotides in the antisense and the sense strands are modified to result in a 2′-O-methyl modification in the sugar residue of the ribonucleotides;
- wherein the ribonucleotides at the 5′ and 3′ termini of the antisense strand are modified to result in the 2′-O-methyl modification;
- wherein the ribonucleotides at the 5′ and 3′ termini of the sense strand are unmodified;
- wherein the antisense and the sense strands are non-phosphorylated at the 3′ and 5′ termini;
- and wherein the compound is between 19-23 nucleotides in length.
2 more elements
A compound having the structure:
- wherein alternating ribonucleotides in the antisense and the sense strands are modified to result in a 2′-O-methyl modification in the sugar residue of the ribonucleotides;
- wherein the ribonucleotides at the 5′ and 3′ termini of the antisense strand are modified to result in the 2′-O-methyl modification;
- wherein the ribonucleotides at the 5′ and 3′ termini of the sense strand are unmodified;
- and wherein the antisense and the sense strands are non-phosphorylated at the 3′ and 5′ termini.
1 more element
Dependencies are inferred from the claim text.